Replies to post #417937 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

NWBO also does not have a CFO who is separate from CEO and probably for the same reasons - having a chief medical/regulatory officer would put someone on the team who might have opinions different than those of Linda Powers and whose expertise etc. could not be easily set aside or ignored.

[Bob_LobLaw]

All by design. no CFO either to offer a checks and balance to how LP decides to finance the company. she can string this out as long as she wants with continued short term financing which dilutes us over and over

[Gus McCrae]

I don’t know why they don’t have a chief medical/regulatory officer on their team who has experience dealing with CROs and regulatory agencies. Unfortunately, the NWBO team have limited insight into who the right folks are and how to deal with them. Don’t understand their strategy.

Yep. It is a huge, huge deal that nobody working for the company has any experience with the BLA process. It is possible that the company has hired a consultant to act as the CRO, but if they have, they have not complied with their duties under the securities laws to tell us that.

From their current cash burn rate, it is obvious that they are not doing any substantial work to get a BLA ready for filing, nor are they doing anything substantial to address commercialization, which I guess makes sense since they must be at least 2 or 3 years away from commercialization. If they released TLD tomorrow, it would take them well over a year to get the BLA filed, and that is assuming they hired a consultant to help them with that process.

[biosectinvestor]

I disagree. Linda is that person.

[Hopeforthefuture3]

Maverick, in the past thermo has suggested that the nwbo management has a lack of experience and I tend to agree. Adding some knowledgeable experienced people in key areas imo would be a great plus.
At least from the Q appears have funds to continue for a few month. Nothing really new or any info on progress - imo
Near 52 week lows, see what SNO brings. Otherwise Bosch is to speak in January assuming they don't cancel
Stay tuned

[Poor Man -]

Here is the one major positive about LP & LG: they’re relatively good at putting together deals. They acquired a controlling interest in NWBO for very little and made a nice deal to sell Sawston, as just two examples.

They’ve used that skill in negative ways as well, but I tend to believe they’re working with Merck - and probably the reason for the quiet period and all of a sudden being timely with their SEC reporting. No buyer wants to acquire another company’s contingencies and legacy issues, especially those that could emerge later.

Unless Merck is working behind the scenes, which seems more and more unlikely given the slow progress.